AUTHORS
Min Xiao, PhD, Juan Peng, MS2, Wei Zhang3, Dongfeng Zeng4, Jia Wei, MD, PhD5
AFFILIATIONS
1 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
3 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
4 Department of Hematology, Daping Hospital, Army Medical University, Chongqing, China, Chongqing, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
ABSTRACT
Background:
Ocular adnexal lymphoma (OAL) represents a heterogeneous group of lymphoid malignancies with diverse pathological subtypes. Although NGS has greatly refined lymphoma classification, systematic genomic profiling of OAL in large cohorts remains limited. This study aims to determine whether distinct pathological subtypes of OAL acquire shared genomic alterations associated with their common anatomical site or retain subtype-specific genetic signatures. Integrative genomic-transcriptomic subclassification of ocular adnexal MALT lymphoma (OA-MALT), the predominant OAL subtype, was performed to identify biologically distinct subgroups with therapeutic relevance.
Methods:
This retrospective study analyzed 148 patients with OAL diagnosed at two medical centers between 2018 and 2024, including 118 cases of mucosa-associated lymphoid tissue (MALT) lymphoma, 16 diffuse large B-cell lymphoma (DLBCL), 4 mantle cell lymphoma (MCL), 4 extranodal NK/T-cell lymphoma (ENKTL), 2 plasmablastic lymphoma (PBL), 2 transformed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 1 CLL/SLL, and 1 transformed follicular lymphoma. Tumor samples underwent targeted NGS using a 220-gene lymphoma panel with recurrent breakpoint detection, and copy number alterations (CNAs) were assessed by low-coverage WGS. In OA-MALT cases, integrated genomic and RNA-seq profiling with unsupervised clustering was performed to define molecular subgroups, followed by DEG and pathway enrichment analyses.
Results
Distinct genomic landscapes among OAL subtypes: With the exception of TNFAIP3 inactivation (encompassing both gene mutations and 6q23 deletions), which was frequently observed in both MALT (63/118) and DLBCL (9/16), the mutation and CNA profiles of each OAL subtype largely resembled those reported in their systemic counterparts, with no evidence of a shared genomic signature associated with the common anatomical site. Specifically, all 4 MCL cases harbored IGH::CCND1 translocations. Among 16 DLBCL cases, 9 cases were classified as MCD subtype, 4 as A53 subtype, and 3 as other subtypes.
Molecular classification of OA-MALT: Based on 118 cases of OA-MALT, the most frequent genetic alterations were TNFAIP3 inactivation (including inactivating mutations and 6q23 deletions, 63/118) and trisomy 3 (46/118). Translocations involving MALT1, BCL10, or FOXP1 were rare (2/118). Through unsupervised clustering integrating genomic aberrations with RNA-seq profiles, three major molecular subtypes were identified.
Cluster 1 (49/118) was predominantly defined by recurrent chromosomal copy-number gains, most prominently trisomy 3 (44/49), frequently accompanied by trisomy 18 (18/49), 6p gain (12/49), trisomy 12 (9/49), and trisomy 15 (8/49). RGS13 was significantly overexpressed in this cluster (p<0.05).
Cluster 2 (33/118) was characterized by impaired negative regulation of NF-κB signaling, driven by TNFAIP3 inactivation (including inactivating mutations and 6q23 deletions, 33/33), with biallelic inactivation observed in 9/33 cases. CD81 was identified as the signature overexpressed gene in this cluster (p<0.05).
Cluster 3 (29/118) featured direct genetic activation of the NF-κB pathway, predominantly driven by TBL1XR1 mutations (10/29) and MYD88 L265P mutations (8/29), which were mutually exclusive (p<0.001). Notably, cases in Cluster 3 rarely coexisted with trisomy 3 (0/10 TBL1XR1-mutant cases and 0/8 MYD88-mutant cases) or with TNFAIP3 inactivation (1/10 TBL1XR1-mutant cases and 0/8 MYD88-mutant cases), underscoring the molecular distinctness of this subtype. The cluster demonstrated marked overexpression of TLR6 (p<0.05).
An additional 7 cases lacking recurrent genetic alterations were excluded from subtype-specific survival analysis. Integrated classification revealed significant differences in progression-free survival among the three clusters (p<0.001), with Cluster 2 showing the most favorable prognosis, followed by Cluster 1 and Cluster 3.
Conclusions:
In summary, TNFAIP3 inactivation is the most prevalent genetic lesion in OAL, while NF-κB pathway activation represents the convergent molecular hallmark of OA-MALT. Integrative genomic-transcriptomic clustering identifies three prognostically distinct OA-MALT subtypes, providing a framework for refined risk stratification and precision therapy in OA-MALT.
DISCLOSURES
Min Xiao, PhD: No relevant conflicts of interest to declare.